Sectoral Asset Management Inc Bio N Tech Se Transaction History

Sectoral Asset Management Inc

$120 Million
Q3 2024

A detailed history of Sectoral Asset Management Inc transactions in Bio N Tech Se stock. As of the latest transaction made, Sectoral Asset Management Inc holds 13,155 shares of BNTX stock, worth $1.54 Million. This represents 1.3% of its overall portfolio holdings.

Number of Shares

13,155

Previous 27,265 51.75%

Holding current value

$1.54 Million

Previous $2.19 Million 28.71%

% of portfolio

1.3%

Previous 1.09%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$78.36 - $124.66 $1.11 Million - $1.76 Million	-14,110 Reduced 51.75%	13,155 $1.56 Million
Q2 2024 Aug 13, 2024	BUY	$80.36 - $102.87 $1.91 Million - $2.44 Million	23,740 Added 673.48%	27,265 $2.19 Million
Q1 2024 May 14, 2024	SELL	$88.96 - $112.35 $17,792 - $22,470	-200 Reduced 5.37%	3,525 $325,000
Q4 2023 Feb 14, 2024	BUY	$90.91 - $112.75 $25,454 - $31,570	280 Added 8.13%	3,725 $393,000
Q3 2023 Nov 14, 2023	BUY	$98.5 - $125.08 $11,426 - $14,509	116 Added 3.48%	3,445 $374,000
Q2 2023 Aug 11, 2023	BUY	$102.58 - $129.66 $64,522 - $81,556	629 Added 23.3%	3,329 $359,000
Q3 2022 Nov 10, 2022	BUY	$127.65 - $183.11 $63,825 - $91,555	500 Added 22.73%	2,700 $364,000
Q2 2022 Aug 15, 2022	SELL	$123.25 - $186.24 $51,765 - $78,220	-420 Reduced 16.03%	2,200 $328,000
Q1 2022 May 10, 2022	SELL	$126.25 - $231.85 $42,293 - $77,669	-335 Reduced 11.34%	2,620 $447,000
Q4 2021 Feb 11, 2022	BUY	$216.64 - $362.52 $401,867 - $672,474	1,855 Added 168.64%	2,955 $762,000
Q3 2021 Nov 15, 2021	BUY	$205.93 - $447.23 $226,523 - $491,953	1,100 New	1,100 $300,000

Others Institutions Holding BNTX

# of Institutions

357

Shares Held

38.3M

Call Options Held

2.45M

Put Options Held

2.29M

View Full List

About BioNTech SE

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $28.4B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

More about BNTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Sectoral Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Sectoral Asset Management Inc with notifications on news.

Account

Sectoral Asset Management Inc Bio N Tech Se Transaction History